Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: An open-label study

International Journal of Clinical Practice

Volumn 63, Issue 4, 2009, Pages 560-567

  Wyndaele, J J ^a   Goldfischer, E R ^b   Morrow, J D ^c   Gong, J ^c   Tseng, L J ^c   Guan, Z ^c   Choo, M S ^d  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b Hudson Valley Urology   (United States)

^c PFIZER INC   (United States)

^d University of Ulsan College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; TOLTERODINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSURIA; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; MORNING DOSAGE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OVERACTIVE BLADDER; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SCORING SYSTEM; TREATMENT RESPONSE; URINARY URGENCY; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIMUTAGENIC AGENTS; BENZHYDRYL COMPOUNDS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE; URINATION; YOUNG ADULT;

EID: 62549133509     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02035.x     Document Type: Article

References (21)

1. Abrams P, Artibani W, Cardozo L et al. Reviewing the ICS 2002 Terminology Report: the ongoing debate. Neurourol Urodyn 2006 25 : 293.
2. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 50 : 1306 15.
3. Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001 87 : 760 6.
4. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 36.
5. Moreland RB, Brioni JD, Sullivan JP. Emerging pharmacologic approaches for the treatment of lower urinary tract disorders. J Pharmacol Exp Ther 2004 308 : 797 804.
6. Ouslander JG. Management of overactive bladder. N Engl J Med 2004 350 : 786 99.
7. Chapple CR, Khullar V, Gabriel Z et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008 54 : 543 62.
8. Tubaro A, De Nunzio C. Comparison of peripherally active substance for treatment of detrusor overactivity: what is new; what is in the pipeline. EAU Update Series 2004 2 : 161 9.
9. Brynne N, Dalen P, Alvan G et al. Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamic of tolterodine. Clin Pharmacol Ther 1998 63 : 529 39.
10. Chapple C, Van Kerrebroeck P, Tubaro A et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007 52 : 1204 12.
11. Kelleher CJ, Tubaro A, Wang JT, Kopp Z. Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int 2008 102 : 56 61.
12. Nitti V, Dmochowski R, Sand P et al. Efficacy, safety, and tolerability of fesoterodine in subjects with overactive bladder. J Urol 2007 178 : 2488 94.
13. Colman S, Chapple C, Nitti V et al. Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder. Urology 2008 72 : 803 7.
14. Coyne KS, Tubaro A, Brubaker L, Bavendam T. Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology 2006 68 : 9 16.
15. Piault E, Evans CJ, Espindle D et al. Development and validation of the Overactive Bladder Satisfaction (OAB-S) Questionnaire. Neurourol Urodyn 2008 27 : 179 90.
16. Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the Patient Perception of Bladder Condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 49 : 1079 86.
17. Cardozo L, Coyne KS, Versi E. Validation of the Urgency Perception Scale. BJU Int 2005 95 : 591 6.
18. Coyne K, Revicki D, Hunt T et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res 2002 11 : 563 74.
19. Coyne K, Matza L, Kopp Z et al. Determining the minimally important difference of the Overactive Bladder Questionnaire (OAB-q). Value Health 2005 8 : A9.
20. Khullar V, Rovner ES, Dmochowski R et al. Fesoterodine dose response in subjects with overactive bladder syndrome. Urology 2008 71 : 839 43.
21. van Leeuwen JHS, Castro R, Busse M, Bemelmans BL. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006 50 : 440 53.